Data presented from the MYTHIC trial showed activity for lunresertib plus zedoresertib in platinum-resistant ovarian cancer, with response rates highest in a biomarker-defined subgroup. For patients overall, the trial reported an ORR of 37.5% across dose levels, rising to 50% at the potential RP2D, and 60% in CCNE1-amplified disease; the FDA granted fast track designation for the regimen.